Phase 2 N=59 Pharmacokinetics of LCP-Tacro in Stable Liver Transplant Patients
Liver Failure
Primary: Evaluation of Steady State Tacrolimus Trough Levels (C24). — 6.72 ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=12 Clinical Study of Peripheral Capillary Oxygen Saturation (SpO2): Vital Signs Patch (VSP)
Desaturation of Blood
Primary: Composite Outcome Measure: Successful Capture of Peripheral Capillary Oxygen Saturation (SpO2) Level — 12 participants
Phase 2 N=93 Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation
Cystic Fibrosis
Primary: Safety and Tolerability Based on Adverse Events (AEs) — 17; 16; 15; 16 participants
Phase 3 N=314 Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)
Hypercholesterolemia
Primary: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--To-Treat (ITT) Analysis — -14.6; -45.0 percent change — p=<0.0001
Phase 1 N=32 Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma
Multiple Myeloma
Primary: Number of Participants Reporting One or More Treatment-Emergent Adverse Events and Serious Adverse Events — 3; 3; 2; 3 participants
Phase 2 N=23 Phase II A Trial of Curcumin Among Patients With Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci)
Healthy, no Evidence of Disease · Tobacco Use Disorder
Primary: Baseline in Prostaglandin E2 (PGE2) Within Aberrant Crypt Foci (ACF) — 1.1; 3.4 µg/g protein
Phase 2 N=134 A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients
Carcinoma, Hepatocellular
Primary: Maximum Tolerated Dose in Phase I — 200; 200 mg
N/A N=25 Virtual Reality & D-cycloserine (DCS) for Posttraumatic Stress Disorder (PTSD)
Posttraumatic Stress Disorder
Primary: Clinician Administered PTSD Scale(CAPS) — 32.38; 42.17 units on a scale
Phase 2 N=59 Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Overall Participant Response Rate: Percentage of Participants With Complete + Partial Response According to Revised National Cancer Institute-sponsored Working Group…
Phase 4 N=300 This Study Aims to Determine the Long-term Persistence of Antibodies Against Hepatitis B and to Evaluate the Immunogenicity and Safety of Hepatitis B Vaccine in Adolescents Vaccinated in Infancy With Infanrix™ Hexa
Hepatitis B
Primary: Anti-HBs Immune Response — 272 Subject
Phase 4 N=90 Low Dose Ketamine Versus Morphine for Moderate to Severe Pain in the Emergency Department
Pain
Primary: Numeric Rating Scale of Pain — 3.93; 4.07 Units on a scale
Phase 1 N=32 Pharmacokinetics of LCZ696 in Subjects With Mild and Moderate Renal Impairment Compared to Healthy Subjects With Normal Renal Function
Mild and Moderate Renal Impairment
Primary: Time to Reach Maximum Peak Plasma Concentration (Tmax) After Single Dose (Day 1), and After Multiple Dose Administration (Day 5) — 1; 0.5; 0.5; 0.5 hr
Phase 2 N=41 Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer
Prostate Cancer
Primary: Prostate-Specific Antigen (PSA) Progression at 1 Year After Completing Androgen Deprivation Therapy (ADT) — 98 percentage of participants with data
N/A N=140 Medication Adherence in Individuals With Epilepsy
Epilepsy
Primary: Raw Count of Number of Days of Medication Nonadherence — 28 % of nonadherence days
Phase 3 N=670 Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML
Myeloid Leukemia, Chronic, Chronic-Phase
Primary: Percent of Participants With Major Cytogenetic Response (MCyR) at 6 Months Follow-Up — 51.8; 49.0 percentage of Participants